Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting

by GlobeNewsWire | Dec 3, 2018 | Globe Newswire

P-BCMA-101 showed a 100% ORR with patients achieving rapid and deep responses with no CRS or neurotoxicity observed at the planned Phase 2 doseSAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) — Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company...

Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-Cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology (ASH) Annual Meeting

by GlobeNewsWire | Dec 3, 2018 | Globe Newswire

Moffitt Cancer Center collaborators described next-generation chimeric antigen receptor T-cell (CAR T) technology that increases T cell persistence and decreases exhaustionMemorial Sloan Kettering collaborators presented positive Phase 2 clinical results for...

ValOre Announces Rights Offering

by GlobeNewsWire | Dec 3, 2018 | Globe Newswire

VANCOUVER, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) — ValOre Metals Corp. (TSX-V: VO) (“ValOre” or the “Company”) today announced that it will conduct an offering (the “Rights Offering”) of rights (“Rights”) to acquire common shares of the Company...

Allogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 in Relapsed/Refractory Acute Lymphoblastic Leukemia  

by GlobeNewsWire | Dec 3, 2018 | Globe Newswire

82 percent of Patients Achieved a Complete Remission when Lymphodepletion Regimen Included an anti-CD52 Monoclonal Antibody (mAb)Safety Profile of UCART19 Appears Manageable with No Evidence of Moderate or Severe Graft-vs-Host Disease (GvHD) and No Severe...

Revasum commences trading on the ASX

by GlobeNewsWire | Dec 3, 2018 | Globe Newswire

Highlights: Revasum to list today at 12.00pm following a fully underwritten Initial Public Offering (IPO) which raised A$30.7 millionThe IPO received strong support from some of Australia’s leading Institutional InvestorsRevasum recently selected as strategic partner...